ArticleBMC cancer2025
CXCR3 gene as a therapeutic target in colorectal cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancers, especially colorectal cancer, are among the most common and deadly diseases in the world, and their incidence is increasing in various countries. Current therapeutic methods, such as chemotherapy, surgery, and immunotherapy, have failed to provide successful treatment without side effects. Therefore, identifying effective therapeutic targets is crucial. Several studies have demonstrated that the expression of the CXCR3 gene, a member of the GPCR family, is elevated in colorectal cancer.
methodsIn this study, the effect of targeting the CXCR3 gene on the HCT-116 line, a colorectal cancer cell line, was investigated via gene-specific targeting. For this purpose, specific DNAzymes were designed, and the impact of CXCR3 downregulation on cancer cell development was assessed via cell cycle analysis, Annexin V-PI staining, and the wound healing method.
resultsCXCR3 gene downregulation inhibited the key AKT‒MTOR pathway and reduced proliferation and growth of HCT-116 cells. Moreover, CXCR3 mRNA downregulation increased the apoptosis of these cells.
conclusionOur findings suggest that downregulation of CXCR3 mRNA inhibits colorectal cancer cell growth through inhibition of the AKT‒mTOR pathway. The CXCR3 receptor can be considered a new therapeutic target in colorectal cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.